HEOR
Unleashing the Value of Innovative Healthcare Technologies
Conquering the Unimaginable
We're motivated by the urgency to generate robust and differentiated value for innovative healthcare technologies entering the market. As a leading value science company, Syenza offers integrated HEOR services that create credible value for our clients. Our unparalleled scientific, strategic, and operational capacity magnify the value of our clients' assets in the Pharma, Medtech, and Biotech industries.
Value Communications
Syenza develops agile,
tech-enabled Global Value
Dossiers and localized HTA
submissions to set in motion
the value of innovative
healthcare technologies. Our
GVDs and HTA submissions
strengthen the interlinkages
between the clinical,
economic and humanistic
outcomes to facilitate
decision-making.
Health Economic Analyses
Syenza reveals the
differentiated value of
innovations by determining
the comprehensive health
economic impact of healthcare
technologies. Our interactive
cost-effectiveness and
budget impact models are
validated before they
inform decision-making on
the value and affordability
of innovations.
Scientific Writing
Syenza is more than just
medical writers; we are
Scientific Partners for your
Business. Our innovative,
fit-for-purpose publication
strategies deliver high-quality
evidence synthesis for early
value communication, payor
engagement, critical
assessment of clinical and
economic outcomes, horizon
scanning, and targeted
evidence reviews.
Service Outcomes
Clients receive actionable insights in Cost-Effectiveness and Budget Impact Technical Reports with a complete Dynamic Model.
Clients deploy our insights to guide the development of GVDs and submissions to HTA agencies.
Clients integrate publishable systematic literature reviews, burden of illness studies, manuscripts, abstracts, and posters.
View Our Recent Articles
NICE Endorses Obecabtagene Autoleucel Therapy for Adult...
Could a UK-developed CAR T therapy significantly improve survival for adults with relapsed B‑cell ALL? 🧬 NICE has recommended obecabtagene autoleucel for adults aged 26+ (subject to a commercial deal), finding impr...
Health Investment Returns: Harnessing Health as a Strategic...
Can health be a nation's most strategic asset? 💡📈 EFPIA’s guest analysis reframes health spending as high-return investment—showing how targeted innovation and earlier care (notably for HER2+ breast cancer) can...
Rethinking Health Technology Assessment: Evolving Economic...
🤔 Is the traditional QALY framework holding back the future of health technology assessment? A recent report from the Health Economics Methods Advisory (HEMA) group suggests it's time for a paradigm shift! By adopting...
